US2007026470A1PendingUtilityA1

Mammalian IAP gene family, primers, probes and detection methods

Assignee: KORNELUK ROBERT GPriority: Aug 4, 1995Filed: Jul 25, 2006Published: Feb 1, 2007
Est. expiryAug 4, 2015(expired)· nominal 20-yr term from priority
A61P 9/10A61P 9/00A61P 43/00A61P 31/18A61P 25/00A61P 31/00A61P 1/00C12Q 2600/136C12Q 2600/118G01N 33/6872A01K 2217/075A01K 2217/05G01N 33/502C12Q 2600/158C12Q 1/6886G01N 2510/00G01N 33/68A61K 48/00G01N 33/5008C12Q 1/6883A61P 1/16C07K 14/4747A61K 38/00C12Q 2600/156G01N 2500/00G01N 33/57557G01N 33/57535G01N 33/57505G01N 33/5752G01N 33/5751
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primer and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.

Claims

exact text as granted — not AI-modified
1 . A substantially pure polypeptide consisting of a sequence having at least 85% sequence identity to SEQ ID NO:22 or amino acids 169-235 of SEQ ID NO:6, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.  
     
     
         2 . The polypeptide of  claim 1 , wherein said polypeptide has at least 85% sequence identity to SEQ ID NO:22.  
     
     
         3 . The polypeptide of  claim 1 , wherein said polypeptide has at least 90% sequence identity to SEQ ID NO: 22.  
     
     
         4 . The polypeptide of  claim 1 , wherein said polypeptide has at least 95% sequence identity to SEQ ID NO 22.  
     
     
         5 . The polypeptide of  claim 1 , wherein said polypeptide has at least 85% sequence identity to amino acids 169-235 of SEQ ID NO:6.  
     
     
         6 . The polypeptide of  claim 1 , wherein said polypeptide has at least 90% sequence identity to amino acids 169-235 of SEQ ID NO:6.  
     
     
         7 . The polypeptide of  claim 1 , wherein said polypeptide has at least 95% sequence identity to amino acids 169-235 of SEQ ID NO:6.  
     
     
         8 . A substantially pure polypeptide consisting of SEQ ID NO:22 or amino acids 169-235 of SEQ ID NO:6, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.  
     
     
         9 . The polypeptide of  claim 8 , wherein said polypeptide has the sequence of SEQ ID NO:22.  
     
     
         10 . The polypeptide of  claim 8 , wherein said polypeptide has the sequence of amino acids 169-235 of SEQ ID NO:22.  
     
     
         11 . A substantially pure polypeptide comprising SEQ ID NO:22 or amino acids 169-235 of SEQ ID NO:6, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.  
     
     
         12 . The polypeptide of  claim 11 , wherein said polypeptide comprises the sequence of SEQ ID NO:22.  
     
     
         13 . The polypeptide of  claim 11 , wherein said polypeptide has the sequence of amino acids 169-235 of SEQ ID NO:6.  
     
     
         14 . A method of identifying a compound that modulates apoptosis, said method comprising: 
 (a) providing a polypeptide of any one of claims  1 - 13 ;    (b) contacting said polypeptide with a candidate compound; and    (c) detecting an interaction between said polypeptide and said candidate compound, wherein an interaction identifies said candidate compound as a compound that modulates apoptosis.

Join the waitlist — get patent alerts

Track US2007026470A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.